The proceeds from the ?IP will be primarily utilized to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Limited
Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized
Biocon will acquire all of Viatris’ convertible preferred equity in Biocon Biologics for $400 million in cash and $415 million in newly issued Biocon shares
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
She was Group Chief Marketing Officer at CKA Birla Group in her last role
The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
The company was awarded the insulins supply contract for a three-year period in 2022 through April 2025
Biocon’s subsidiary Biocon Biologics Limited, which also participated independently in the assessment for the first time, reported an S&P Global ESG Score of 53
Successfully transformed the organization from a two-country operation focused on development and manufacturing to a fully integrated company with a strong commercial engine bringing us closer to patients in over 120 countries
Subscribe To Our Newsletter & Stay Updated
